Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H23FN4OS.2ClH |
Molecular Weight | 459.408 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.CC1=C(NC(=O)[C@@H](N)CCCCN)C=CC(=C1)C2=NC3=C(S2)C=CC(F)=C3
InChI
InChIKey=QZSMNTOCJVVFEU-CKUXDGONSA-N
InChI=1S/C20H23FN4OS.2ClH/c1-12-10-13(20-25-17-11-14(21)6-8-18(17)27-20)5-7-16(12)24-19(26)15(23)4-2-3-9-22;;/h5-8,10-11,15H,2-4,9,22-23H2,1H3,(H,24,26);2*1H/t15-;;/m0../s1
Molecular Formula | C20H23FN4OS |
Molecular Weight | 386.486 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:18:26 UTC 2023
by
admin
on
Sat Dec 16 11:18:26 UTC 2023
|
Record UNII |
AXR52N9SMF
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
328087-38-3
Created by
admin on Sat Dec 16 11:18:26 UTC 2023 , Edited by admin on Sat Dec 16 11:18:26 UTC 2023
|
PRIMARY | |||
|
5F-DF-203-L-LYSINAMIDE
Created by
admin on Sat Dec 16 11:18:26 UTC 2023 , Edited by admin on Sat Dec 16 11:18:26 UTC 2023
|
PRIMARY | Substd. 2-arylbenzazole cpds. and their use as antitumour agents. | ||
|
SUB194064
Created by
admin on Sat Dec 16 11:18:26 UTC 2023 , Edited by admin on Sat Dec 16 11:18:26 UTC 2023
|
PRIMARY | |||
|
9804228
Created by
admin on Sat Dec 16 11:18:26 UTC 2023 , Edited by admin on Sat Dec 16 11:18:26 UTC 2023
|
PRIMARY | |||
|
PHORTRESS
Created by
admin on Sat Dec 16 11:18:26 UTC 2023 , Edited by admin on Sat Dec 16 11:18:26 UTC 2023
|
PRIMARY | Phortress rapidly reverts to 5-fluoro 203 in carcinoma cell lines, resulting in significant growth inhibition at nanomolar concentrations.2 At 20 mg/kg, phortress can suppress the growth of breast and ovarian xenografts in vivo. | ||
|
710305
Created by
admin on Sat Dec 16 11:18:26 UTC 2023 , Edited by admin on Sat Dec 16 11:18:26 UTC 2023
|
PRIMARY | |||
|
100000178336
Created by
admin on Sat Dec 16 11:18:26 UTC 2023 , Edited by admin on Sat Dec 16 11:18:26 UTC 2023
|
PRIMARY | |||
|
AXR52N9SMF
Created by
admin on Sat Dec 16 11:18:26 UTC 2023 , Edited by admin on Sat Dec 16 11:18:26 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
In 2002, DDG approved the development of Phortress as a clinical candidate and provided synthesis, formulation, pharmacokinetic, and toxicity resources.
|